Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study
BACKGROUND Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic...
Gespeichert in:
| Veröffentlicht in: | Transfusion (Philadelphia, Pa.) Pa.), 2016-04, Vol.56 (4), p.827-830 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 830 |
|---|---|
| container_issue | 4 |
| container_start_page | 827 |
| container_title | Transfusion (Philadelphia, Pa.) |
| container_volume | 56 |
| creator | Napolitano, Mariasanta Gerardi, Calogera Di Lucia, Anna Accardo, Pietro Andrea Rizzuto, Luigi Ferraro, Maria Siragusa, Sergio Buscemi, Filippo |
| description | BACKGROUND
Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.
STUDY DESIGN AND METHODS
Peripheral circulating CD34+ stem cells, colony‐forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF‐GEMM), colony‐forming unitgranulocyte/macrophage (CFU‐GM), and erythroidburst‐forming units (BFU‐E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy controls. Demographic and clinical data were recorded.
RESULTS
Overall, 56 patients with TM (median age, 35 years; range, 13‐52 years) and 13 with TI (median age, 44 years; range, 27‐67 years) were evaluated. Annual red blood cell (RBC) transfusion requirements ranged from 10 to 65 units in all patients except four nontransfused cases. A significant increase in peripheral circulating stem cells was observed in patients, in comparison with healthy controls. Nontransfused patients showed the mean highest levels of stem cells (CD34, 32.5 ± 14.8/μL; BFU‐E, 41.3 ± 22.8/mL; CFU‐GM, 19.6 ± 5.6/mL; CFU‐GEMM, 9.0 ± 6.1/mL). CD34+ cell count was 6.9 ± 4.5/μL in TM (p = 0.014) and 11.8 ± 14.8/μL (p = 0.051) in TI. Furthermore, only in patients with TI was a significant increase in CFU‐GEMM (3.0 ± 4.8 vs. 0.75 ± 2.05/mL, p = 0.0001) observed. At multivariate analysis, peripheral circulating CD34+ stem cells did not correlate with age, sex, smoking habit, number of RBCs units transfused, Hb levels, iron chelation therapy, history of splenectomy, and hypothyroidism.
CONCLUSION
Circulating peripheral CD34 + stem cells are increased in β‐thalassemia, in particular in nontransfused patients, compared to healthy controls. |
| doi_str_mv | 10.1111/trf.13452 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1781539702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2123738140</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4262-cb1421fb84c354ffc935cda5a471356c6bb22acc739ee04be5eea19999ebe5133</originalsourceid><addsrcrecordid>eNp1kd1qFDEUx4Modlu98AUk4I29mDYfk_nwTortCqVCXellyGTO7KZmkmmSoe5TCT6Iz2TWbXsheAjJgfM7_yTnj9AbSk5ojtMUhhPKS8GeoQUVvC5Y24rnaEFISQtKOTtAhzHeEkJYS-hLdMCqhlBB2wX6uYRRJT95A8loPEEw0waCsliboGerknFr3FnvexwTjFiDtRGrvBw2rocJ8uYSHlX4DgH7Aa93bArKxWGOxrtccmoN444yDk9ZMqcR35u0wb9_FWmjrIoRRqM-4ABxtrk4BD9ihacA1ozGqbDN18_99hV6MSgb4fXDeYS-nX9anS2Lyy8Xn88-Xha6ZBUrdEdLRoeuKTUX5TDolgvdK6HKmnJR6arrGFNa17wFIGUHAkDRNgfknHJ-hN7vdafg72aISY4m7v6uHPg5Slo3edJtTVhG3_2D3vo5uPw6ySjjNW9oSTJ1vKd08DEGGOQUTB7aVlIidy7K7KL862Jm3z4ozt0I_RP5aFsGTvfAvbGw_b-SXF2fP0oW-w6TXfzx1JFNk1XNayFvri7k16slI9c3K9nwP7ibuwM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2123738140</pqid></control><display><type>article</type><title>Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Napolitano, Mariasanta ; Gerardi, Calogera ; Di Lucia, Anna ; Accardo, Pietro Andrea ; Rizzuto, Luigi ; Ferraro, Maria ; Siragusa, Sergio ; Buscemi, Filippo</creator><creatorcontrib>Napolitano, Mariasanta ; Gerardi, Calogera ; Di Lucia, Anna ; Accardo, Pietro Andrea ; Rizzuto, Luigi ; Ferraro, Maria ; Siragusa, Sergio ; Buscemi, Filippo</creatorcontrib><description>BACKGROUND
Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.
STUDY DESIGN AND METHODS
Peripheral circulating CD34+ stem cells, colony‐forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF‐GEMM), colony‐forming unitgranulocyte/macrophage (CFU‐GM), and erythroidburst‐forming units (BFU‐E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy controls. Demographic and clinical data were recorded.
RESULTS
Overall, 56 patients with TM (median age, 35 years; range, 13‐52 years) and 13 with TI (median age, 44 years; range, 27‐67 years) were evaluated. Annual red blood cell (RBC) transfusion requirements ranged from 10 to 65 units in all patients except four nontransfused cases. A significant increase in peripheral circulating stem cells was observed in patients, in comparison with healthy controls. Nontransfused patients showed the mean highest levels of stem cells (CD34, 32.5 ± 14.8/μL; BFU‐E, 41.3 ± 22.8/mL; CFU‐GM, 19.6 ± 5.6/mL; CFU‐GEMM, 9.0 ± 6.1/mL). CD34+ cell count was 6.9 ± 4.5/μL in TM (p = 0.014) and 11.8 ± 14.8/μL (p = 0.051) in TI. Furthermore, only in patients with TI was a significant increase in CFU‐GEMM (3.0 ± 4.8 vs. 0.75 ± 2.05/mL, p = 0.0001) observed. At multivariate analysis, peripheral circulating CD34+ stem cells did not correlate with age, sex, smoking habit, number of RBCs units transfused, Hb levels, iron chelation therapy, history of splenectomy, and hypothyroidism.
CONCLUSION
Circulating peripheral CD34 + stem cells are increased in β‐thalassemia, in particular in nontransfused patients, compared to healthy controls.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.13452</identifier><identifier>PMID: 26801519</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Age ; Aged ; beta-Thalassemia - blood ; beta-Thalassemia - diagnosis ; beta-Thalassemia - therapy ; Biomarkers - blood ; Blood circulation ; Blood transfusion ; Case-Control Studies ; CD34 antigen ; Chelation ; Colonies ; Demographics ; Erythrocytes ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Hematopoietic Stem Cells - pathology ; Hemoglobin ; Humans ; Hypothyroidism ; Iron ; Macrophages ; Male ; Middle Aged ; Multivariate analysis ; Patients ; Pilot Projects ; Prognosis ; Smoking ; Splenectomy ; Stem cells ; Thalassemia ; Transfusion ; Treatment Outcome ; Young Adult</subject><ispartof>Transfusion (Philadelphia, Pa.), 2016-04, Vol.56 (4), p.827-830</ispartof><rights>2016 AABB</rights><rights>2016 AABB.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4262-cb1421fb84c354ffc935cda5a471356c6bb22acc739ee04be5eea19999ebe5133</citedby><cites>FETCH-LOGICAL-c4262-cb1421fb84c354ffc935cda5a471356c6bb22acc739ee04be5eea19999ebe5133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftrf.13452$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftrf.13452$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26801519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Napolitano, Mariasanta</creatorcontrib><creatorcontrib>Gerardi, Calogera</creatorcontrib><creatorcontrib>Di Lucia, Anna</creatorcontrib><creatorcontrib>Accardo, Pietro Andrea</creatorcontrib><creatorcontrib>Rizzuto, Luigi</creatorcontrib><creatorcontrib>Ferraro, Maria</creatorcontrib><creatorcontrib>Siragusa, Sergio</creatorcontrib><creatorcontrib>Buscemi, Filippo</creatorcontrib><title>Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>BACKGROUND
Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.
STUDY DESIGN AND METHODS
Peripheral circulating CD34+ stem cells, colony‐forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF‐GEMM), colony‐forming unitgranulocyte/macrophage (CFU‐GM), and erythroidburst‐forming units (BFU‐E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy controls. Demographic and clinical data were recorded.
RESULTS
Overall, 56 patients with TM (median age, 35 years; range, 13‐52 years) and 13 with TI (median age, 44 years; range, 27‐67 years) were evaluated. Annual red blood cell (RBC) transfusion requirements ranged from 10 to 65 units in all patients except four nontransfused cases. A significant increase in peripheral circulating stem cells was observed in patients, in comparison with healthy controls. Nontransfused patients showed the mean highest levels of stem cells (CD34, 32.5 ± 14.8/μL; BFU‐E, 41.3 ± 22.8/mL; CFU‐GM, 19.6 ± 5.6/mL; CFU‐GEMM, 9.0 ± 6.1/mL). CD34+ cell count was 6.9 ± 4.5/μL in TM (p = 0.014) and 11.8 ± 14.8/μL (p = 0.051) in TI. Furthermore, only in patients with TI was a significant increase in CFU‐GEMM (3.0 ± 4.8 vs. 0.75 ± 2.05/mL, p = 0.0001) observed. At multivariate analysis, peripheral circulating CD34+ stem cells did not correlate with age, sex, smoking habit, number of RBCs units transfused, Hb levels, iron chelation therapy, history of splenectomy, and hypothyroidism.
CONCLUSION
Circulating peripheral CD34 + stem cells are increased in β‐thalassemia, in particular in nontransfused patients, compared to healthy controls.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>beta-Thalassemia - blood</subject><subject>beta-Thalassemia - diagnosis</subject><subject>beta-Thalassemia - therapy</subject><subject>Biomarkers - blood</subject><subject>Blood circulation</subject><subject>Blood transfusion</subject><subject>Case-Control Studies</subject><subject>CD34 antigen</subject><subject>Chelation</subject><subject>Colonies</subject><subject>Demographics</subject><subject>Erythrocytes</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Hematopoietic Stem Cells - pathology</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Hypothyroidism</subject><subject>Iron</subject><subject>Macrophages</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Pilot Projects</subject><subject>Prognosis</subject><subject>Smoking</subject><subject>Splenectomy</subject><subject>Stem cells</subject><subject>Thalassemia</subject><subject>Transfusion</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd1qFDEUx4Modlu98AUk4I29mDYfk_nwTortCqVCXellyGTO7KZmkmmSoe5TCT6Iz2TWbXsheAjJgfM7_yTnj9AbSk5ojtMUhhPKS8GeoQUVvC5Y24rnaEFISQtKOTtAhzHeEkJYS-hLdMCqhlBB2wX6uYRRJT95A8loPEEw0waCsliboGerknFr3FnvexwTjFiDtRGrvBw2rocJ8uYSHlX4DgH7Aa93bArKxWGOxrtccmoN444yDk9ZMqcR35u0wb9_FWmjrIoRRqM-4ABxtrk4BD9ihacA1ozGqbDN18_99hV6MSgb4fXDeYS-nX9anS2Lyy8Xn88-Xha6ZBUrdEdLRoeuKTUX5TDolgvdK6HKmnJR6arrGFNa17wFIGUHAkDRNgfknHJ-hN7vdafg72aISY4m7v6uHPg5Slo3edJtTVhG3_2D3vo5uPw6ySjjNW9oSTJ1vKd08DEGGOQUTB7aVlIidy7K7KL862Jm3z4ozt0I_RP5aFsGTvfAvbGw_b-SXF2fP0oW-w6TXfzx1JFNk1XNayFvri7k16slI9c3K9nwP7ibuwM</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Napolitano, Mariasanta</creator><creator>Gerardi, Calogera</creator><creator>Di Lucia, Anna</creator><creator>Accardo, Pietro Andrea</creator><creator>Rizzuto, Luigi</creator><creator>Ferraro, Maria</creator><creator>Siragusa, Sergio</creator><creator>Buscemi, Filippo</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201604</creationdate><title>Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study</title><author>Napolitano, Mariasanta ; Gerardi, Calogera ; Di Lucia, Anna ; Accardo, Pietro Andrea ; Rizzuto, Luigi ; Ferraro, Maria ; Siragusa, Sergio ; Buscemi, Filippo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4262-cb1421fb84c354ffc935cda5a471356c6bb22acc739ee04be5eea19999ebe5133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>beta-Thalassemia - blood</topic><topic>beta-Thalassemia - diagnosis</topic><topic>beta-Thalassemia - therapy</topic><topic>Biomarkers - blood</topic><topic>Blood circulation</topic><topic>Blood transfusion</topic><topic>Case-Control Studies</topic><topic>CD34 antigen</topic><topic>Chelation</topic><topic>Colonies</topic><topic>Demographics</topic><topic>Erythrocytes</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Hematopoietic Stem Cells - pathology</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Hypothyroidism</topic><topic>Iron</topic><topic>Macrophages</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Pilot Projects</topic><topic>Prognosis</topic><topic>Smoking</topic><topic>Splenectomy</topic><topic>Stem cells</topic><topic>Thalassemia</topic><topic>Transfusion</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Napolitano, Mariasanta</creatorcontrib><creatorcontrib>Gerardi, Calogera</creatorcontrib><creatorcontrib>Di Lucia, Anna</creatorcontrib><creatorcontrib>Accardo, Pietro Andrea</creatorcontrib><creatorcontrib>Rizzuto, Luigi</creatorcontrib><creatorcontrib>Ferraro, Maria</creatorcontrib><creatorcontrib>Siragusa, Sergio</creatorcontrib><creatorcontrib>Buscemi, Filippo</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Napolitano, Mariasanta</au><au>Gerardi, Calogera</au><au>Di Lucia, Anna</au><au>Accardo, Pietro Andrea</au><au>Rizzuto, Luigi</au><au>Ferraro, Maria</au><au>Siragusa, Sergio</au><au>Buscemi, Filippo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2016-04</date><risdate>2016</risdate><volume>56</volume><issue>4</issue><spage>827</spage><epage>830</epage><pages>827-830</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><abstract>BACKGROUND
Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.
STUDY DESIGN AND METHODS
Peripheral circulating CD34+ stem cells, colony‐forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF‐GEMM), colony‐forming unitgranulocyte/macrophage (CFU‐GM), and erythroidburst‐forming units (BFU‐E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy controls. Demographic and clinical data were recorded.
RESULTS
Overall, 56 patients with TM (median age, 35 years; range, 13‐52 years) and 13 with TI (median age, 44 years; range, 27‐67 years) were evaluated. Annual red blood cell (RBC) transfusion requirements ranged from 10 to 65 units in all patients except four nontransfused cases. A significant increase in peripheral circulating stem cells was observed in patients, in comparison with healthy controls. Nontransfused patients showed the mean highest levels of stem cells (CD34, 32.5 ± 14.8/μL; BFU‐E, 41.3 ± 22.8/mL; CFU‐GM, 19.6 ± 5.6/mL; CFU‐GEMM, 9.0 ± 6.1/mL). CD34+ cell count was 6.9 ± 4.5/μL in TM (p = 0.014) and 11.8 ± 14.8/μL (p = 0.051) in TI. Furthermore, only in patients with TI was a significant increase in CFU‐GEMM (3.0 ± 4.8 vs. 0.75 ± 2.05/mL, p = 0.0001) observed. At multivariate analysis, peripheral circulating CD34+ stem cells did not correlate with age, sex, smoking habit, number of RBCs units transfused, Hb levels, iron chelation therapy, history of splenectomy, and hypothyroidism.
CONCLUSION
Circulating peripheral CD34 + stem cells are increased in β‐thalassemia, in particular in nontransfused patients, compared to healthy controls.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26801519</pmid><doi>10.1111/trf.13452</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1132 |
| ispartof | Transfusion (Philadelphia, Pa.), 2016-04, Vol.56 (4), p.827-830 |
| issn | 0041-1132 1537-2995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1781539702 |
| source | MEDLINE; Wiley Online Library Journals |
| subjects | Adolescent Adult Age Aged beta-Thalassemia - blood beta-Thalassemia - diagnosis beta-Thalassemia - therapy Biomarkers - blood Blood circulation Blood transfusion Case-Control Studies CD34 antigen Chelation Colonies Demographics Erythrocytes Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hematopoietic Stem Cells - pathology Hemoglobin Humans Hypothyroidism Iron Macrophages Male Middle Aged Multivariate analysis Patients Pilot Projects Prognosis Smoking Splenectomy Stem cells Thalassemia Transfusion Treatment Outcome Young Adult |
| title | Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T17%3A02%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hematopoietic%20peripheral%20circulating%20blood%20stem%20cells%20as%20an%20independent%20marker%20of%20good%20transfusion%20management%20in%20patients%20with%20%CE%B2-thalassemia:%20results%20from%20a%20preliminary%20study&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Napolitano,%20Mariasanta&rft.date=2016-04&rft.volume=56&rft.issue=4&rft.spage=827&rft.epage=830&rft.pages=827-830&rft.issn=0041-1132&rft.eissn=1537-2995&rft_id=info:doi/10.1111/trf.13452&rft_dat=%3Cproquest_cross%3E2123738140%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2123738140&rft_id=info:pmid/26801519&rfr_iscdi=true |